The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Meanwhile, the MHRA has also warned all people seeking treatment with the so-called "skinny jabs" to beware of counterfeit ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

Europe follows a similar pattern, with data from the EU Clinical Trials Information System (CTIS) estimating that less than 0 ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

Only approximately two out of 10 people in the US and three out of 10 people in Europe with certain rare, advanced blood ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

With Axtria Ignite 2025 just around the corner, attention turns to how the life sciences industry is preparing for the next ...

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head ...

At ASCO 2025, pharmaphorum web editor Nicole Raleigh sat down to discuss key highlights from the Congress with EVERSANA experts.

Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...